AMPUTATION AND ADRIAMYCIN IN PRIMARY OSTEOSARCOMA
AMPUTATION AND ADRIAMYCIN IN PRIMARY OSTEOSARCOMA
复制标题
DOI：
10.1056/nejm197411072911903
复制
发表时间：
1974-01-01
影响因子：
158.5
通讯作者：
GLIDEWELL, O
中科院分区：
文献类型：
--
作者：
CORTES, EP;HOLLAND, JF;GLIDEWELL, O
阿霉素对转移性骨肉瘤有效。为了确定其在骨肉瘤中的疗效，没有检测到转移，21例患者在手术切除原发病灶后两周（中位数）给予辅助阿霉素治疗。给予6个疗程的阿霉素（每天每平方米30 mg，共3天，每4 - 6周重复一次）。21例患者中有19例术后生存时间超过1个月至32个月（中位数超过9个月）。21例中有5例复发（2例局部复发，3例肺转移）。根据生命表分析，18个月时，预计71%的治疗患者可能没有肺转移（95%置信限，100%至43%），与Marcove等分析的145例患者中的30%相反，这些数据表明阿霉素在延迟骨肉瘤的大体转移方面具有作用，并且与化疗根除微转移。（《新英格兰医学杂志》291：998-1000，1974）
Adriamycin has been found effective in metastatic osteogenic sarcoma. To determine its efficacy in osteosarcoma without detectable metastases, 21 patients were given adjuvant adriamycin therapy two weeks (median) after surgical amputation of the primary lesion. Six courses of adriamycin (30 mg per square meter daily for three days, repeated every four to six weeks) were administered. Nineteen of the 21 patients survived from more than one to more than 32 months (median, more than nine months) after operation. Five of the 21 relapsed (two with local and three with pulmonary metastases). At 18 months, 71 per cent of treated patients may be expected to be free of pulmonary metastases as determined by life-table analyses (95 per cent confidence limits, 100 to 43 per cent), in contrast to 30 per cent of the series of 145 patients analyzed by Marcove et al. The data demonstrate an effect of adriamycin in delaying gross metastases from osteosarcoma and are consistent with chemotherapeutic eradication of micrometastases. (N Engl J Med 291:998–1000, 1974)